Brief: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance
17/04/2024 14:24
April 17 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS RECEIVES NASDAQ-APPROVED EXTENSION
TO
REGAIN COMPLIANCE WITH NASDAQ LISTING RULE 5550(B)(1)
Source text for Eikon: ID:nGNXbyk64T
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic